Donor Selection in T Cell–Replete Haploidentical Hematopoietic Stem Cell Transplantation: Knowns, Unknowns, and Controversies
Open Access
- 28 February 2013
- journal article
- review article
- Published by Elsevier BV in Transplantation and Cellular Therapy
- Vol. 19 (2), 180-184
- https://doi.org/10.1016/j.bbmt.2012.08.007
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood graftsBlood, 2011
- Outcomes of Patients with Myeloid Malignancies Treated with Allogeneic Hematopoietic Stem Cell Transplantation from Matched Unrelated Donors Compared with One Human Leukocyte Antigen Mismatched Related Donors Using HLA Typing at 10 LociTransplantation and Cellular Therapy, 2011
- Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCTBone Marrow Transplantation, 2011
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemiaBlood, 2010
- Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow TransplantationTransplantation and Cellular Therapy, 2010
- Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on OutcomeTransplantation and Cellular Therapy, 2010
- A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantationBlood, 2008
- Survival after T cell–depleted haploidentical stem cell transplantation is improved using the mother as donorBlood, 2008
- Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletionLeukemia, 2007
- Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipientsBlood, 2006